Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database

Date
2021
Author
Arikan, Rukiye
Yekeduz, Emre
Erturk, Ismail
Tural, Deniz
Karadurmus, Nuri
Karakaya, Serdar
Hizal, Mutlu
Arslan, Cagatay
Taban, Hakan
Kucukarda, Ahmet
oztas, Nihan Senturk
Sever, ozlem Nuray
Ucar, Gokhan
Can, Orcun
Nahit Sendur, Mehmet Ali
Demirci, Umut
KILIÇKAP, SAADETTİN
ÇİÇİN, İRFAN
Oksuzoglu, Berna
ozguroglu, Mustafa
ÜRÜN, YÜKSEL
Metadata
Show full item record
Abstract
Lay abstract Nivolumab is an immune checkpoint inhibitor (ICI) that blocks the communication between T cells and cancer cells and instead activates T cells to fight against cancer. Metastatic renal cell carcinoma (mRCC) is one of the most susceptible tumors to ICIs. The Checkmate 025 trial showed the efficacy of nivolumab in patients with previously treated mRCC. In this real-world study, 173 patients with mRCC were treated with nivolumab in the second line and beyond. Nivolumab was effective in the real-world setting without additional safety concerns.
URI
http://hdl.handle.net/20.500.12627/171840
https://doi.org/10.2217/fon-2021-0717
Collections